These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12523918)

  • 1. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia.
    Umans-Eckenhausen MA; Defesche JC; van Dam MJ; Kastelein JJ
    Arch Intern Med; 2003 Jan; 163(1):65-8. PubMed ID: 12523918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.
    Huijgen R; Kindt I; Verhoeven SB; Sijbrands EJ; Vissers MN; Kastelein JJ; Hutten BA
    PLoS One; 2010 Feb; 5(2):e9220. PubMed ID: 20169164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Screening for familial hypercholesterolemia from low-density lipoprotein cholesterol levels at admission in the coronary care unit].
    Chemaly P; Nallet O; Delarche N; Legagneur C; Boulestreau R; Reibel I; Palette C; Grenier A; Courtade H; Beaune G; Belle L; Georges JL
    Ann Cardiol Angeiol (Paris); 2018 Nov; 67(5):300-309. PubMed ID: 30290906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.
    Græsdal A; Bogsrud MP; Holven KB; Nenseter MS; Narverud I; Langslet G; Brekke M; Retterstøl K; Arnesen KE; Ose L
    J Clin Lipidol; 2012; 6(4):331-9. PubMed ID: 22836070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical determinants and treatment gaps in familial hypercholesterolemia: Data from a multi-ethnic regional health service.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Eur J Prev Cardiol; 2017 May; 24(8):867-875. PubMed ID: 28186442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
    Perez de Isla L; Alonso R; Watts GF; Mata N; Saltijeral Cerezo A; Muñiz O; Fuentes F; Diaz-Diaz JL; de Andrés R; Zambón D; Rubio-Marin P; Barba-Romero MA; Saenz P; Sanchez Muñoz-Torrero JF; Martinez-Faedo C; Miramontes-Gonzalez JP; Badimón L; Mata P;
    J Am Coll Cardiol; 2016 Mar; 67(11):1278-85. PubMed ID: 26988947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Awareness, treatment rates, and compliance to treatment in patients with serum LDL cholesterol higher than 250 mg/dL, and possible, probable, or definite familial hypercholesterolemia.
    Yaman S; Ozdemir D; Akman BT; Cakir B; Ersoy O
    Postgrad Med; 2021 Mar; 133(2):146-153. PubMed ID: 32744105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.
    Saltijeral A; Pérez de Isla L; Alonso R; Muñiz O; Díaz-Díaz JL; Fuentes F; Mata N; de Andrés R; Díaz-Soto G; Pastor J; Pinilla JM; Zambón D; Pinto X; Badimón L; Mata P;
    Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):444-450. PubMed ID: 27913073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare Utilization and Patients' Perspectives After Receiving a Positive Genetic Test for Familial Hypercholesterolemia.
    Jones LK; Kulchak Rahm A; Manickam K; Butry L; Lazzeri A; Corcoran T; Komar D; Josyula NS; Pendergrass SA; Sturm AC; Murray MF
    Circ Genom Precis Med; 2018 Aug; 11(8):e002146. PubMed ID: 30354341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in Statin studies with familial hypercholesterolemia (ExPRESS FH).
    de Sauvage Nolting PR; Buirma RJ; Hutten BA; Kastelein JJ;
    Atherosclerosis; 2002 Oct; 164(2):347-54. PubMed ID: 12204807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
    Mabuchi H; Koizumi J; Kajinami K
    Am J Cardiol; 1998 Aug; 82(4B):52J-55J. PubMed ID: 9737647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil.
    Souto AC; Miname MH; Fukushima J; Jannes CE; Krieger JE; Hagger M; Pereira AC; Santos RD
    Atherosclerosis; 2018 Oct; 277():464-469. PubMed ID: 30270086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
    Peters TK
    Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.
    Brunham LR; Cermakova L; Lee T; Priecelova I; Alloul K; de Chantal M; Francis GA; Frohlich J
    Can J Cardiol; 2017 Mar; 33(3):385-392. PubMed ID: 27931859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
    Leitersdorf E; Muratti EN; Eliav O; Meiner V; Eisenberg S; Dann EJ; Sehayek E; Peters TK; Stein Y
    Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.